SlideShare uma empresa Scribd logo
1 de 18
Information on rare cancers Kathy Redmond Editor, Cancer World Magazine
 
Raising public awareness about rare cancers: challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The goal of raising awareness in rare cancers is to ensure that patients with are diagnosed in a timely manner and gain access to state-of-the-art care
Possible solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Working with the media is a double edged sword
Increasing non-specialist knowledge about rare cancers: challenges faced ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Occam's razor and medicine ,[object Object],[object Object],[object Object],[object Object],[object Object]
Possible solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Increasing exchange of information among rare cancer specialists: challenges faced ,[object Object],[object Object],[object Object],[object Object]
Possible solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ESO’s e-grandround: an innovative approach to educting health professionals across Europe
Increasing patients’ knowledge about rare cancers: challenges faced ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Possible Solutions ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Increasing policy makers’ awareness about rare cancers: challenges faced ,[object Object],[object Object],[object Object]
Possible solutions ,[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Semelhante a Raising Awareness of Rare Cancers Faces Many Challenges

Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...European School of Oncology
 
Social Media-Rare Disease (Luis Luque, Manuel Armayones)
Social Media-Rare Disease (Luis Luque, Manuel Armayones)Social Media-Rare Disease (Luis Luque, Manuel Armayones)
Social Media-Rare Disease (Luis Luque, Manuel Armayones)Manuel Armayones
 
Spearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithakaSpearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithakaKesho Conference
 
Breast Cancer030310
Breast Cancer030310Breast Cancer030310
Breast Cancer030310klee4vp
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointIMSHealthRWES
 
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!Baltic PR Awards
 
Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...patvocates
 
Disease awareness campaign awareness pm360 3
Disease awareness campaign awareness pm360 3Disease awareness campaign awareness pm360 3
Disease awareness campaign awareness pm360 3DarrenKong4
 
Report launch: The invisible epidemic – Rethinking the detection and treatmen...
Report launch: The invisible epidemic – Rethinking the detection and treatmen...Report launch: The invisible epidemic – Rethinking the detection and treatmen...
Report launch: The invisible epidemic – Rethinking the detection and treatmen...ILC- UK
 
The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...jangeissler
 
Integrating Wellness Into Cancer Care
Integrating Wellness Into Cancer CareIntegrating Wellness Into Cancer Care
Integrating Wellness Into Cancer CareCurrent Oncology
 
121220 wcd2013 toolkit
121220 wcd2013 toolkit121220 wcd2013 toolkit
121220 wcd2013 toolkitGreg in SD
 
Introduction practice is a major emphasis in modern health.docx
Introduction practice is a major emphasis in modern health.docxIntroduction practice is a major emphasis in modern health.docx
Introduction practice is a major emphasis in modern health.docxstudywriters
 
Challenges and Opportunities 07082022 Conference.pptx
Challenges and Opportunities 07082022 Conference.pptxChallenges and Opportunities 07082022 Conference.pptx
Challenges and Opportunities 07082022 Conference.pptxFredasirwa
 
Vivid Consumer Mini Capabilities 09
Vivid Consumer Mini Capabilities 09Vivid Consumer Mini Capabilities 09
Vivid Consumer Mini Capabilities 09lillianthiemann
 
PowerPoint Presentation +.ppt
PowerPoint Presentation +.pptPowerPoint Presentation +.ppt
PowerPoint Presentation +.pptShaan73
 

Semelhante a Raising Awareness of Rare Cancers Faces Many Challenges (20)

Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
Rare Solid Cancers: An Introduction - Slide 5 - J. Geissler - Patient advocac...
 
rj pdf.pdf
rj pdf.pdfrj pdf.pdf
rj pdf.pdf
 
Social Media-Rare Disease (Luis Luque, Manuel Armayones)
Social Media-Rare Disease (Luis Luque, Manuel Armayones)Social Media-Rare Disease (Luis Luque, Manuel Armayones)
Social Media-Rare Disease (Luis Luque, Manuel Armayones)
 
Spearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithakaSpearheading cancer awareness by benda kithaka
Spearheading cancer awareness by benda kithaka
 
Breast Cancer030310
Breast Cancer030310Breast Cancer030310
Breast Cancer030310
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpoint
 
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!
Corporate sustainability & responsibility 2007 / 1st Place / Izvēlies dzīvot!
 
Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...Access to treatment, care and clinical trials by patients with rare cancers...
Access to treatment, care and clinical trials by patients with rare cancers...
 
Disease awareness campaign awareness pm360 3
Disease awareness campaign awareness pm360 3Disease awareness campaign awareness pm360 3
Disease awareness campaign awareness pm360 3
 
Karen Harrison
Karen HarrisonKaren Harrison
Karen Harrison
 
HOPE Presentation
HOPE PresentationHOPE Presentation
HOPE Presentation
 
Global goal setting: a pathway to results 2.5 x 2025
Global goal setting: a pathway to results 2.5 x 2025Global goal setting: a pathway to results 2.5 x 2025
Global goal setting: a pathway to results 2.5 x 2025
 
Report launch: The invisible epidemic – Rethinking the detection and treatmen...
Report launch: The invisible epidemic – Rethinking the detection and treatmen...Report launch: The invisible epidemic – Rethinking the detection and treatmen...
Report launch: The invisible epidemic – Rethinking the detection and treatmen...
 
The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...The benefits of patient involvement in research and development (RE:ACT Congr...
The benefits of patient involvement in research and development (RE:ACT Congr...
 
Integrating Wellness Into Cancer Care
Integrating Wellness Into Cancer CareIntegrating Wellness Into Cancer Care
Integrating Wellness Into Cancer Care
 
121220 wcd2013 toolkit
121220 wcd2013 toolkit121220 wcd2013 toolkit
121220 wcd2013 toolkit
 
Introduction practice is a major emphasis in modern health.docx
Introduction practice is a major emphasis in modern health.docxIntroduction practice is a major emphasis in modern health.docx
Introduction practice is a major emphasis in modern health.docx
 
Challenges and Opportunities 07082022 Conference.pptx
Challenges and Opportunities 07082022 Conference.pptxChallenges and Opportunities 07082022 Conference.pptx
Challenges and Opportunities 07082022 Conference.pptx
 
Vivid Consumer Mini Capabilities 09
Vivid Consumer Mini Capabilities 09Vivid Consumer Mini Capabilities 09
Vivid Consumer Mini Capabilities 09
 
PowerPoint Presentation +.ppt
PowerPoint Presentation +.pptPowerPoint Presentation +.ppt
PowerPoint Presentation +.ppt
 

Mais de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Mais de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

Raising Awareness of Rare Cancers Faces Many Challenges

  • 1. Information on rare cancers Kathy Redmond Editor, Cancer World Magazine
  • 2.  
  • 3.
  • 4. The goal of raising awareness in rare cancers is to ensure that patients with are diagnosed in a timely manner and gain access to state-of-the-art care
  • 5.
  • 6.  
  • 7. Working with the media is a double edged sword
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.

Notas do Editor

  1. Occam's razor: The principle of scientific or, in medicine, diagnostic parsimony or "unitarianism." In medicine, a clinician would like to be able to use Occam's razor and come up with a unifying diagnosis that will explain all of the patient's problems. "Although we generally like to invoke Occam's razor, for some patients we cannot follow the rule of diagnostic parsimony." (New Engl J Med 350: 600, 2004). William of Occam in the 14th century stated this principle: "The assumptions introduced to explain a thing must not be multiplied beyond necessity." When discussing Occam's razor in contemporary medicine , doctors and philosophers of medicine speak of diagnostic parsimony. Diagnostic parsimony advocates that when diagnosing a given injury, ailment, illness, or disease a doctor should strive to look for the fewest possible causes that will account for all the symptoms. This philosophy is one of several demonstrated in the popular medical adage " when you are in Texas and you hear hoofbeats, think horses, not zebras ." While diagnostic parsimony might often be beneficial, credence should also be given to the counter-argument modernly known as Hickam's dictum , which succinctly states that "patients can have as many diseases as they damn well please." It is often statistically more likely that a patient has several common diseases, rather than having a single rarer disease which explains their myriad symptoms. Also, independently of statistical likelihood, some patients do in fact turn out to have multiple diseases, which by common sense nullifies the approach of insisting to explain any given collection of symptoms with one disease. These misgivings emerge from simple probability theory—which is already taken into account in many modern variations of the razor—and from the fact that the loss function is much greater in medicine than in most of general science. Because misdiagnosis can result in the loss of a person's health and potentially life, it is considered better to test and pursue all reasonable theories even if there is some theory that appears the most likely. Diagnostic parsimony and the counter-balance it finds in Hickam's dictum have very important implications in medical practice. Any set of symptoms could be indicative of a range of possible diseases and disease combinations; though at no point is a diagnosis rejected or accepted just on the basis of one disease appearing more likely than another, the continuous flow of hypothesis formulation, testing and modification benefits greatly from estimates regarding which diseases (or sets of diseases) are relatively more likely to be responsible for a set of symptoms, given the patient's environment, habits, medical history and so on. For example, if a hypothetical patient's immediately apparent symptoms include fatigue and cirrhosis and they test negative for Hepatitis C , their doctor might formulate a working hypothesis that the cirrhosis was caused by their drinking problem , and then seek symptoms and perform tests to formulate and rule out hypotheses as to what has been causing the fatigue; but if the doctor were to further discover that the patient's breath inexplicably smells of garlic and they are suffering from pulmonary edema , they might decide to test for the relatively rare condition of Selenium poisoning . Prior to effective anti-retroviral therapy for HIV it was frequently stated that the most obvious implication of Occam's razor, that of cutting down the number of postulated diseases to a minimum, does not apply to patients with AIDS , as they frequently did have multiple infectious processes going on at the same time. While the probability of multiple diseases being higher certainly reduces the degree to which this kind of analysis is useful, it does not go all the way to invalidating it altogether; even in such a patient, it would make more sense to first test a theory postulating three diseases to be the cause of the symptoms than a theory postulating seven.